Zimmer Biomet sets quarterly dividend at $0.24 per share

WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a prominent player in the medical technology industry with a market capitalization of $21.38 billion, has declared a quarterly cash dividend for stockholders for Q1 of 2025. The dividend, set at $0.24 per share, representing a yield of 0.89%, will be distributed on or around April 30, 2025, to shareholders on record as of March 31, 2025. According to InvestingPro, the company has maintained dividend payments for 13 consecutive years.

This announcement reflects the company’s ongoing commitment to providing returns to its investors. Zimmer Biomet has a history of delivering medical technology solutions aimed at enhancing patient care and improving health outcomes, maintaining a robust gross profit margin of 71.71%. The company’s extensive portfolio includes a range of innovative products and services, which are supported by advanced digital and robotic technologies. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.

Zimmer Biomet has established a strong reputation over its 90-year history, founded on leadership and expertise in the medical technology field. The company operates in over 25 countries and markets its products in more than 100 countries globally.

The dividend payment is in line with Zimmer Biomet’s strategic financial practices and is part of the company’s efforts to maximize shareholder value. It also indicates the Board of Directors’ confidence in the firm’s financial stability and future prospects.

Investors and stockholders can anticipate the dividend payment towards the end of April, following the close of the record date at the end of March. This news is based on a press release statement from Zimmer Biomet Holdings, Inc.

In other recent news, Zimmer Biomet Holdings, Inc. announced the issuance of $1.75 billion in new notes, with varying interest rates and maturity dates, as part of its financial strategy. The company also provided updates on its pending merger with Paragon 28, Inc., indicating specific conditions under which certain notes would be redeemed. Additionally, Zimmer Biomet’s leadership changes were highlighted with President and CEO Ivan Tornos set to become Chairman of the Board following the retirement of Christopher Begley. Meanwhile, Citi analysts maintained a Neutral rating on Zimmer Biomet with a price target of $118, noting conservative full-year guidance and foreign exchange pressures. Truist Securities adjusted its price target to $113 from $118, maintaining a Hold rating due to lower earnings per share guidance for 2025, which was below consensus estimates. Despite a modest beat in fourth-quarter organic revenue and operating profit, the potential impact of the upcoming FNA deal was noted. Analysts at Truist acknowledged the conservative revenue outlook and potential product launches that could drive growth in the latter half of 2025. Zimmer Biomet’s strategic moves, including potential share buybacks, are being closely watched by investors as the company navigates its financial landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.